Humulin N (Nph) Cartridge (Insulin Human (Rdna))

Humulin N (Nph) Cartridge contains insulin human produced by recombinant DNA technology. It is supplied as a cartridge for use with an insulin pen, intended for subcutaneous injection. The product is a prescription‑only, EU‑marketed basal insulin formulation that provides intermediate‑acting glucose control for people with diabetes.

Humulin N is prescribed to manage blood glucose levels in diabetes mellitus. It is used as part of a comprehensive diabetes treatment plan that may include diet, exercise, and other medications.

- Long‑acting basal insulin for Type 1 diabetes mellitus. - Long‑acting basal insulin for Type 2 diabetes mellitus. - Supplemental insulin therapy when rapid‑acting insulin is insufficient. - Combination therapy with mealtime insulin analogues. - Adjusted dosing for patients requiring stable overnight glucose control.

Adverse reactions to Humulin N may vary in frequency and severity.

Common: - Injection site pain or erythema. - Hypoglycemia (low blood glucose). - Lipodystrophy at injection sites. - Weight gain. - Edema or fluid retention.

Serious: - Severe hypoglycemia leading to loss of consciousness. - Allergic reactions such as urticaria, angioedema, or anaphylaxis. - Persistent hyperglycemia indicating possible insulin resistance. - Rare cases of insulin antibody formation.

Before starting Humulin N, patients should be evaluated for factors that may affect insulin therapy.

- Review history of hypoglycemia unawareness or severe episodes. - Assess renal or hepatic impairment, which may alter insulin clearance. - Monitor during pregnancy or lactation; adjust dosing as needed. - Caution in patients with cardiovascular disease due to potential fluid shifts. - Educate on proper injection technique to reduce lipodystrophy. - Ensure regular blood glucose monitoring to avoid over‑correction.

Certain drugs can modify the glucose‑lowering effect of Humulin N.

Avoid: - Concurrent use of other insulin products without dose adjustment. - High‑dose sulfonylureas that may precipitate severe hypoglycemia. - Beta‑blockers masking hypoglycemia symptoms.

Use with caution: - Oral antihyperglycemics (e.g., metformin, thiazolidinediones) requiring dose titration. - Corticosteroids that increase glucose levels. - Diuretics that may affect fluid balance and insulin absorption. - ACE inhibitors or ARBs, which can potentiate hypoglycemia in some patients.